By Inside Your Peptides · Two FDA letters issued 24 August 2026 · Source checked 2026-09-17
A research-use label is easy to spot. The surrounding evidence takes longer to read. Two FDA letters issued on 24 August 2026 make that difference unusually clear: the agency described human-use intent despite disclaimers on the sellers’ websites.
This is a close reading of two public records, checked on 17 September 2026. It is not a ranking of vendors, a claim that every research seller is the same, or a prediction of what enforcement will happen next.
What the letters actually say
In its letter to NuScience Peptides, FDA said website evidence established intended human-drug uses despite laboratory-use and no-human-use language. The agency pointed to the surrounding product claims and presentation, including materials and tools associated with preparing injectable products. These are the agency’s stated reasons, not claims that we have independently established.
The letter to TXP Innovations, doing business as Tex Peptides, makes a similar distinction. FDA acknowledged research-use disclaimers but identified other website evidence as supporting human-use intent. Both letters characterized products as unapproved new drugs. Neither is a laboratory report identifying the composition of a particular vial.
Why the document type matters
A warning letter communicates the agency’s assessment and seeks correction. It should not be converted into a claim that a court has ruled, that every listed product was chemically tested, or that a company’s status cannot change. FDA’s warning-letter page explicitly cautions that subsequent interactions with recipients may change regulatory status.
The reverse shortcut is also unreliable. Not finding a letter is not a quality certificate. It does not answer whether a report is authentic, whether it matches the offered lot, or whether a specific test was performed. An enforcement search and a laboratory-document review answer different questions.
Read the page, not only the footer
For your own evidence notes, capture the claim you are evaluating before collecting reassuring badges. Save its exact wording, the original page, and the date. Place the disclaimer beside the surrounding product description and any linked instructions. The goal is to see the entire presentation, not to decide a seller’s legal status from one sentence.
Next, separate three folders: regulatory records, scientific evidence, and material-specific test documents. A trial publication belongs in the scientific folder. An agency letter belongs in the regulatory folder. A laboratory report belongs in the material folder. A strong-looking item in one folder does not fill an empty space in another.
If you are checking a report, record the laboratory, accession, client or submitter, stated sample source, dates, and exact lot. List the tests actually reported rather than writing “fully tested.” Leave unanswered items visibly unanswered. The research-use phrase itself cannot supply any of those missing fields.
If you are checking a regulatory claim, ask for the relevant agency document and its current context. Do not rely on a cropped screenshot or an old summary without a date. Keep your notes descriptive: “the agency letter states…” is more accurate than declaring an unresolved firm permanently compliant or noncompliant.
FAQ
Does a research-use label prove material is safe?
No. A label is not a measurement and does not establish sterility or clinical suitability. It also does not tell you which sample a laboratory received.
Can these letters tell me which supplier to choose?
Not by themselves. They describe two specific agency records. They do not provide a comparative audit of suppliers or material-specific test results.
Why name the sources rather than repeat the sellers’ claims?
The source is the news. Repeating therapeutic marketing as if it were established evidence would reproduce the confusion this article is trying to resolve.
The takeaway: a disclaimer should be read in context, and a regulatory record should be read as the kind of record it is. Keep marketing, scientific findings, and exact-sample testing separate.
Sources and scope
Source links checked 2026-09-17. A source check is not confirmation of every underlying claim.